Composition for preventing or treating salivary gland diseases, comprising epithelial progenitor cells or stem cells in minor salivary gland duct
The use of epithelial progenitor cells or stem cells from minor salivary gland ducts, cultured with specific inhibitors, addresses the limitations of current treatments for salivary gland diseases by restoring salivary gland function and alleviating inflammation, offering a promising regenerative therapy.
Patent Information
- Application Number
- PCT/KR2024/095778
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-17
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-21
AI Technical Summary
Current treatments for salivary gland diseases, particularly Sjögren's syndrome, lack effective curative methods, relying on symptomatic relief and facing challenges with cell therapeutics due to issues like proliferation rate, telomere length, pluripotency markers, and cell senescence, leading to slow progress in clinical trials.
A pharmaceutical composition containing epithelial progenitor cells or stem cells from minor salivary gland ducts, selectively cultured and proliferated using ROCK inhibitors, TGF-beta inhibitors, and BMP inhibitors, which can differentiate into various salivary gland cells, offering a regenerative approach for treating salivary gland diseases.
The composition effectively alleviates inflammation, normalizes saliva production, and restores salivary gland function, providing direct differentiation, immunomodulatory, anti-fibrotic, and growth factor paracrine effects, with excellent therapeutic efficacy and safety, even under xeno-free, serum-free conditions.
Smart Images

Figure KR2024095778_21112024_PF_FP_ABST
Abstract
Description
Composition for preventing or treating salivary gland disease comprising epithelial progenitor cells or stem cells in the salivary gland duct
[0001] The present invention relates to a pharmaceutical composition for preventing or treating salivary gland diseases, which comprises epithelial progenitor cells or stem cells in the salivary gland ducts.
[0002] Salivary gland disease refers to a disease in which the salivary glands have difficulty functioning normally due to damage or inflammation of the salivary gland tissue. Examples of the above salivary gland diseases include xerostomia, infectious acute sialadenitis, infectious chronic sialadenitis, salivary tuberculosis, Sjogren's syndrome, sialolithiasis, salivary duct stenosis, sialadenosis, salivary gland tumors, and salivary gland dysfunction due to aging.
[0003] Among salivary gland diseases, Sjögren's syndrome is an autoimmune disease that mainly occurs in middle-aged and older women. It is a disease in which lymphocytes invade glandular organs in the body, such as the salivary glands, lacrimal glands, and pancreas, for unknown reasons. A representative symptom is irreversible dry mouth caused by decreased salivary gland function. Although clinical trials are being conducted to treat Sjögren's syndrome, methods such as utilizing monoclonal antibodies, which are used to treat various autoimmune diseases, have not yet reported effective results.
[0004] In other words, currently, there is no radical treatment for Sjogren's syndrome or a method to maintain long-term improvement, so only symptomatic treatment using artificial saliva and pyloric acid is used for treatment.
[0005] In this regard, numerous research and development efforts are underway on treatment methods utilizing cell therapy and other cell-based therapies. However, cell therapies still face challenges related to their quality (proliferation rate, telomere length, pluripotency markers, and multilineage differentiation capacity), such as intercellular heterogeneity and cell senescence. Consequently, clinical trials based on these cells are progressing significantly slower.
[0006] Accordingly, the inventors of the present invention have completed the present invention by confirming that inflammation in the salivary gland can be alleviated and saliva production function can be normalized using novel salivary gland duct epithelial precursor cells or stem cells that have been selectively cultured and proliferated.
[0007] The present invention provides a pharmaceutical composition for preventing or treating salivary gland diseases, which comprises epithelial progenitor cells or stem cells in the salivary gland ducts.
[0008] To avoid confusion due to overlapping content, the description of redundant content will be omitted below. In other words, the invention is not limited to the content described below, and the invention should be interpreted based on the overall scope of the invention.
[0009] The present invention seeks to provide a pharmaceutical composition for preventing or treating salivary gland diseases, which comprises epithelial progenitor cells or stem cells in the salivary gland ducts.
[0010] In the present invention, “salivary gland” means an organ that produces and secretes saliva.
[0011] The salivary glands are classified into major salivary glands such as the parotid gland, submaxillary gland, and sublingual gland, and minor salivary glands distributed in various parts of the oral mucosa, such as mucous glands that exist in the mucous membrane of the oral cavity.
[0012] In the present invention, “salivary gland duct” refers to a passage that connects the saliva from the salivary gland to the oral cavity, and includes the parotid duct (Stensen duct), the submandibular duct (Wharton duct), the sublingual duct (Rivinus duct), etc.
[0013] In the present invention, “progenitor cell” means a cell that is committed to differentiating into a specific type of cell or forming a specific type of tissue.
[0014] In the present invention, "stem cell" refers to an undifferentiated cell capable of differentiating into various types of tissue. These stem cells can self-renew through repeated divisions, and can also differentiate into cells with specific functions depending on the environment.
[0015] In the present invention, “epithelial” means a state of being made of epithelium, a membrane tissue covering the inside and outside of the body surface, or having characteristics related thereto.
[0016] The epithelial progenitor cells or stem cells according to the present invention may be derived from a major salivary gland or a minor salivary gland, and preferably from a minor salivary gland. In the present invention, the epithelial progenitor cells or stem cells in the minor salivary gland duct are interpreted to include not only each of the epithelial progenitor cells or stem cells in the minor salivary gland duct, but also all of them.
[0017] Specifically, the epithelial progenitor cells or stem cells of the minor salivary gland duct according to the present invention refer to progenitor cells derived from small saliva-secreting ducts distributed in various places in the mouth. Specifically, it may be a cell capable of self-renewal and having the ability to differentiate into a cell existing in the duct of the minor salivary gland epithelial parenchyma. The epithelial progenitor cells or stem cells of the minor salivary gland duct may be a cell capable of differentiating into another salivary gland cell in the salivary gland epithelial parenchyma.
[0018] "Differentiation" can refer to the phenomenon in which a cell's structure or function becomes specialized during cell division, proliferation, and growth. More specifically, the epithelial progenitor cells or stem cells within the salivary gland ducts can differentiate into basal cells, luminal duct cells, glandular cells, myoepithelial cells, etc. within the salivary gland parenchyma.
[0019] More specifically, the epithelial progenitor cells or stem cells in the salivary gland ducts according to the present invention are CD49f + and CD26 _ may contain salivary gland basal cells.
[0020] Accordingly, the epithelial progenitor cells or stem cells within the salivary gland ducts according to the present invention include cells having characteristics of salivary gland epithelial tissue and also cells having characteristics of salivary gland basal cells. In addition, they exhibit excellent characteristics in that they can have the ability to regenerate salivary glands by possessing multipotent differentiation into basal, luminal, acinar, and myoepithelial cells, which are parenchymal cells within the salivary gland.
[0021] The epithelial progenitor cells or stem cells in the salivary gland duct according to the present invention may be cultured by treating the epithelial progenitor cells or stem cells in the salivary gland duct with a medium composition containing a ROCK inhibitor, a TGF-beta inhibitor, and a bone morphogenetic protein (BMP) inhibitor.
[0022] The epithelial progenitor cells or stem cells within the above-mentioned minor salivary gland duct may be cells derived from minor salivary gland tissue.
[0023] In the present invention, by applying a chemically induced reprogramming method, uniform cells, i.e., epithelial progenitor cells or stem cells in the ducts of the minor salivary glands, are selectively isolated, and at the same time, a medium composition suitable for their survival and proliferation is applied, thereby isolating and using only cell sources suitable for treatment. Furthermore, through rapid proliferation of monoclonal cells of epithelial progenitor cells or stem cells in the ducts of the minor salivary glands, a large quantity of desired cells can be obtained in a short period of time without a WCB (Working Cell Bank) manufacturing step, making it possible to provide cells and a manufacturing method suitable for rapid clinical application together.
[0024] The salivary gland tissue according to the present invention may be derived from any individual, preferably a human. Preferably, it may be derived from an adult human. More preferably, it may be autologous salivary gland tissue. Such salivary gland tissue may be obtained from a 1-2 mm piece of tissue biopsy. 2 It may be isolated from a small amount of tissue within. It is possible to isolate and culture a sufficient quantity of salivary gland epithelial ductal progenitor cells or stem cells under chemically defined culture conditions according to the present invention. That is, target cells can be sufficiently obtained in a desired quantity by culturing them through chemically induced reprogramming using a combination of small molecule compounds.
[0025] Culturing of any of the above-mentioned salivary gland derived cells can be performed in the presence of a ROCK inhibitor, a TGF-beta inhibitor and a bone morphogenetic protein (BMP) inhibitor.
[0026] The above ROCK (Rho-associated protein kinase) inhibitor inhibits the activity of serine / threonine kinase, which acts as a target protein for Rho (Rho A, Rho B, and Rho C), and may be R-(+)-trans-4-(1-Aminoethyl)-N-(4-pyridyl)cyclohexane carboxamide dihydrochloride monohydrate (Y-27632), Fasudil, or H-1152. Preferably, it may be Y-27632. More preferably, it may be 1 to 20 μM of Y-27632.
[0027] The TGF-beta inhibitor is any substance that inhibits the function of the TGF-beta receptor, for example, a protein, a peptide, a small molecule, and may be A83-01, SB-431542, SB-505124, SB-525334, SD-208, RepSOX, LY-36494, and / or SJN-2511. Preferably, it may be A83-01. More preferably, it may be 0.2 to 2 μM of A83-01.
[0028] The BMP inhibitor is an agent that binds to a BMP molecule to form a complex, binds to a BMP receptor, and prevents the binding of a BMP ligand to the receptor, for example, an antibody that binds to the receptor. The BMP inhibitor may be a protein or a small molecule, and may be natural, modified, and / or partially or fully synthetic. In addition, the BMP inhibitor may be Noggin, Dorsomorphin, Gremlin 1, DMH1, and / or LDN-193189. Preferably, it may be DMH1 or LDN-193189. More preferably, the medium composition may comprise DMH1 at a final concentration of 0.1 to 2 μM or LDN193189 at a final concentration of 0.05 to 0.5 μM.
[0029] Preferably, it may be cultured under Y-27632, A83-01, and DMH1 or LDN193189.
[0030] Specifically, it may be cultured under Y-27632, A83-01, and DMH1.
[0031] Specifically, it may be cultured under Y-27632, A83-01, and LDN193189. If necessary, antibiotics may be further included in the culture medium.
[0032] In the culture medium mentioned above, a conventional basal medium can be used. The basal medium is any basal medium suitable for animal or human cells, subject to the limitations provided herein.
[0033] The basal medium for the above-described animal or human cell culture typically contains a number of components necessary to support the maintenance of the cultured cells. Suitable combinations of components can be readily formulated by a skilled practitioner, taking into account the following. The basal medium for use in the present invention will generally comprise a nutrient solution containing literature and standard cell culture components, such as amino acids, vitamins, lipid supplements, mineral salts, carbon energy sources, and buffers. In some embodiments, the culture medium is further supplemented with one or more standard cell culture components selected from, for example, amino acids, vitamins, liquid supplements, mineral salts, carbon energy sources, and buffers.
[0034] The skilled person will understand from common general knowledge the types of culture media that may be used as the basic media in the differentiation media of the present invention. Potentially suitable cell culture media are commercially available and may include, but are not limited to, Dulbecco's Modified Eagle's Medium (DMEM), Minimum Essential Medium (MEM), Knockout-DMEM (KO-DMEM), Glasgow's Minimum Essential Medium (G-MEM), Basal Eagle's Medium (BME), DMEM / Hamm's F12, Advanced DMEM / Hamm's F12, Iscove's Modified Dulbecco's Media and Minimum Essential Medium (MEM), Ham's F-10, Ham's F-12, Medium 199, and RPMI 1640 media.
[0035] Additionally, an epithelial cell culture medium may be used. Specifically, it may be an epithelial cell culture medium such as CNT20, Cnt50, CnT-PR, KSFM, DermaCult, etc. For example, it includes DermaCult™ Keratinocyte Expansion Medium or CnT-PR (CELLnTEC) Medium. For example, the basic medium may be DermaCult™ Keratinocyte Expansion Medium or CnT-PR (CELLnTEC Medium). More preferably, it may be CnT-PR (CELLnTEC) Medium.
[0036] As needed, Prinmocin TM and / or Dermacult Supplement TM may include more.
[0037] The epithelial progenitor cells or stem cells in the ducts of the minor salivary glands according to the present invention can be produced through the steps of (1) culturing (preferably, chemically induced reprogramming) cells derived from the minor salivary glands in a medium composition containing a ROCK inhibitor, a TGF-beta inhibitor, and a bone morphogenetic protein (BMP) inhibitor; and (2) culturing and proliferating the epithelial progenitor cells or stem cells in the ducts of the minor salivary glands cultured and separated in step (1) in a medium containing the ROCK inhibitor, the TGF-beta inhibitor, and the bone morphogenetic protein (BMP) inhibitor.
[0038] More specifically, it can be manufactured through the steps of (1) culturing (preferably chemically induced reprogramming) cells derived from the minor salivary gland under a medium composition containing Y-27632, A83-01, and DMH1 or LDN193189; and (2) culturing and proliferating epithelial progenitor cells or stem cells within the minor salivary gland ducts cultured and separated in step (1) under a medium containing Y-27632, A83-01, and DMH1 or LDN193189.
[0039] More specifically, it can be manufactured through the steps of (1) culturing (preferably, chemically induced reprogramming) cells derived from the minor salivary gland under a medium composition containing Y-27632, A83-01, and DMH1; and (2) culturing and proliferating epithelial progenitor cells or stem cells within the minor salivary gland ducts isolated by culturing in step (1) under a medium containing Y-27632, A83-01, and DMH1.
[0040] More specifically, (1) culturing (preferably, chemically induced reprogramming) cells derived from the minor salivary gland under a medium composition containing Y-27632, A83-01, and LDN193189; and (2) culturing and proliferating epithelial progenitor cells or stem cells within the minor salivary gland ducts cultured and separated in step (1) under a medium containing Y-27632, A83-01, and LDN193189; The cells derived from the minor salivary gland according to the present invention may be obtained from minor salivary gland tissue. Since the minor salivary gland tissue is in a tissue-formed state, various cells exist in the tissue. That is, if passage 1 (P1) cells in a proliferated state are used, they do not exhibit uniform characteristics due to the mixing of various cells, and it is not desirable to utilize such non-uniform cells in terms of clinical applications. Accordingly, in the present invention, epithelial progenitor cells or stem cells in the salivary gland duct are obtained under the culture composition mentioned above, and selectively cultured and proliferated to provide epithelial progenitor cells or stem cells in the salivary gland duct having uniform characteristics.
[0041] The epithelial progenitor cells or stem cells in the salivary gland ducts above can stably form organoids through three-dimensional culture, and unlike cells cultured through a general subculture method, the population doubling is very fast even in a two-dimensional culture method, allowing for easy acquisition of a large number of cells, and the level of cell aging is very low, and they are excellent in terms of proliferation and differentiation ability, and are also excellent in safety in the human body.
[0042] The epithelial progenitor cells or stem cells within the salivary gland ducts above highly express one or more cell surface markers selected from the group consisting of CD29, CD44, CD49f, CD146, and CD166. In addition, they do not express or express at low levels one or more cell surface markers selected from the group consisting of CD24, CD26, CD34, CD90, and CD117.
[0043] Also, CD49f + and CD26 - Contains a high proportion of salivary gland basal cells.
[0044] According to one embodiment, the epithelial progenitor cells or stem cells in the ducts of the minor salivary glands according to the present invention may be characterized by expressing KRT5 and / or E-Cadherin. The KRT5 corresponds to a marker of salivary gland basal duct cells, and the E-Cadherin corresponds to a marker of salivary gland epithelial cells.
[0045] In addition, the epithelial progenitor cells or stem cells in the salivary gland ducts according to the present invention may be characterized by expressing at least one selected from the group consisting of KRT5 and KRT19. The KRT5 and KRT19 correspond to markers of salivary gland duct basal cells or salivary gland duct progenitor cells.
[0046] In addition, the epithelial progenitor cells or stem cells in the salivary gland ducts according to the present invention may be characterized in that they do not express any one or more selected from the group consisting of CDKN2A, Fibronectin-1, and Vimentin. The CDKN2A corresponds to a senescent cell marker, and the Fibronectin-1 and Vimentin correspond to mesenchymal stem cell markers.
[0047] More preferably, the culturing of epithelial progenitor cells or stem cells within the salivary gland duct according to the present invention may further include a step of proliferating monoclonal cells of the epithelial progenitor cells or stem cells within the salivary gland duct. This is preferably performed in the presence of a ROCK inhibitor, a TGF-beta inhibitor, and a bone morphogenetic protein (BMP) inhibitor.
[0048] In clinical applications, obtaining an appropriate number of cells with equivalent therapeutic properties is crucial. Therefore, by using a culture method in the presence of a ROCK inhibitor, a TGF-beta inhibitor, and a bone morphogenetic protein (BMP) inhibitor according to the present invention, it is possible to provide a large quantity of (monoclonal) cells capable of safely differentiating into minor salivary gland cells from a small amount of salivary gland tissue in a short period of time using a two-dimensional culture method while minimizing DNA damage and suppressing senescence, effectively maintaining differentiation potential.
[0049] The step of proliferating the above monoclonal cells is to proliferate monoclonal stem cells at 50 to 1000 cells / cm 2 (cells / cm 2 ) and culturing the cells. This can induce rapid proliferation of monoclonal stem cells, thereby enabling rapid acquisition of the final product. In addition, cells obtained in this manner exhibit excellent effects in the treatment of salivary gland diseases.
[0050] In particular, it has the advantage of being able to provide cells with excellent proliferative capacity and therapeutic efficacy even under xeno-free, serum-free, and feeder-free conditions.
[0051] In order to obtain monoclonal minor salivary gland ductal epithelial progenitor cells or stem cells from the above minor salivary gland tissue, subfractionation culturing method can be preferably used, but is not limited thereto.
[0052] In the present invention, "subfractionation culturing method" refers to a method of separating stem cells according to specific gravity. It refers to a process of first extracting cells from the aforementioned minor salivary gland tissue or minor salivary gland ducts, culturing them in a cell culture medium, then obtaining only the supernatant, transferring it to a culture vessel treated with or without a coating agent, and culturing it, and repeating the same process several times. This subfractionation culturing is characterized by repeating the process of repeatedly obtaining and culturing the supernatant without a centrifugation process, and ultimately has the advantage of being able to obtain minor salivary gland ductal progenitor cells or stem cells without contamination of other cells. In particular, by obtaining a monoclone of minor salivary gland ductal progenitor cells or stem cells having the characteristics of epithelial stem cells in this process, only cells having excellent therapeutic efficacy for salivary gland diseases can be provided.
[0053] In the present invention, the layer separation culture may specifically include a) a step of transferring the supernatant from a first container to a second container; and b) a step of culturing cells present in the second container to obtain a supernatant. More specifically, the steps of a) transferring the supernatant from the first container to a second container; and b) culturing cells present in the second container to obtain a supernatant may be repeated at least once to five times, for example, once, twice, three times, four times, or five times.
[0054] The present invention provides epithelial progenitor cells or stem cells within the ducts of minor salivary glands cultured under a medium composition containing a ROCK inhibitor, a TGF-beta inhibitor, and a bone morphogenetic protein (BMP) inhibitor.
[0055] More specifically, the present invention provides a monoclonal cell of an epithelial progenitor cell or stem cell in a salivary gland duct, manufactured through (1) a step of subfractionation culturing cells derived from a salivary gland under a medium composition containing a ROCK inhibitor, a TGF-beta inhibitor, and a bone morphogenetic protein (BMP) inhibitor; and (2) a step of culturing and proliferating an epithelial progenitor cell or stem cell isolated from a salivary gland duct under a medium composition containing a ROCK inhibitor, a TGF-beta inhibitor, and a bone morphogenetic protein (BMP) inhibitor.
[0056] These monoclonal cells of epithelial progenitor cells or stem cells within the salivary gland ducts possess the characteristics of epithelial stem cells and the ability to differentiate into various cells within the salivary gland. They also exhibit the expression characteristics of the aforementioned markers.
[0057] The present invention provides a pharmaceutical composition comprising epithelial progenitor cells or stem cells within the salivary gland duct.
[0058] The present invention provides a pharmaceutical composition for preventing or treating salivary gland diseases, which comprises epithelial progenitor cells or stem cells in the salivary gland ducts.
[0059] In particular, the composition according to the present invention can be utilized for therapeutic purposes as a bioengineering technique to restore the function of cells or tissues. For example, the pharmaceutical composition can be utilized as a transplant material and applied to the treatment of various salivary gland diseases. In particular, it can be considered for use as a material for the regeneration and reconstruction of damaged (including dysfunctional) salivary gland tissue. Therefore, the pharmaceutical composition according to the present invention can be a tissue therapeutic agent.
[0060] In the present invention, “salivary gland disease” means a condition in which the salivary glands have difficulty functioning normally due to damage to the salivary gland tissue or the occurrence of inflammation, and includes xerostomia, infectious acute sialadenitis, infectious chronic sialadenitis, salivary gland tuberculosis, Sjogren's syndrome, sialolithiasis, salivary duct stenosis, sialadenosis, salivary gland tumor, salivary gland dysfunction due to aging, salivary gland dysfunction due to drugs, and salivary gland dysfunction due to radiation therapy. Preferably, it may be Sjogren's syndrome. The above Sjogren's syndrome is a type of autoimmune disease that mainly occurs in middle-aged and older women, and refers to a disease in which lymphocytes invade glandular organs in the body, such as the salivary glands, tear glands, and pancreas, for unknown reasons.
[0061] In the present invention, the term “prevention” refers to any act of inhibiting or delaying the onset of a salivary gland disease by administering a pharmaceutical composition according to the present invention.
[0062] In the present invention, the term “treatment” refers to any act of improving or beneficially changing the symptoms of a salivary gland disease by administering a composition according to the present invention.
[0063] The composition according to the present invention exhibits excellent preventive and therapeutic efficacy against diseases by having direct differentiation, immunomodulatory, antifibrotic, and growth factor paracrine effects.
[0064] According to one embodiment, the composition according to the present invention can restore salivary gland function by dose-dependently restoring salivary secretion ability to a normal level and reducing damage to salivary gland ducts.
[0065] The pharmaceutical composition of the present invention may be formulated and provided in an appropriate form. In addition to the effective ingredient, the cell, the composition may be manufactured by including one or more pharmaceutically acceptable carriers.
[0066] In addition, the pharmaceutical composition of the present invention can be formulated into a unit dosage form pharmaceutical preparation suitable for administration into the patient's body according to a conventional method in the pharmaceutical field and administered, and the preparation contains an effective dosage amount through one or more administrations. Preferred dosage forms for this purpose are parenteral administration preparations such as injections and infusions. The administration dosage of the pharmaceutical composition may vary depending on the patient's age, weight, sex, dosage form, health condition, and disease severity, and may be administered once or several times a day at regular intervals according to the judgment of a doctor or pharmacist.
[0067] The route and method of administration of the pharmaceutical composition of the present invention may be independent of each other, and are not particularly limited in their method, and any route and method of administration may be followed as long as the pharmaceutical composition can reach the target area.
[0068] Preferably, the pharmaceutical composition of the present invention can be administered directly into a duct, preferably a salivary gland duct, of a patient in need of treatment.
[0069] If necessary, it is administered with an extracellular matrix. The extracellular matrix includes, but is not limited to, fibrin, laminin, collagen, and / or alginate. Examples of extracellular matrix-producing cells include chondrocytes, which primarily produce collagen and proteoglycans; fibroblasts, which primarily produce type IV collagen, laminin, interstitial procollagen, and fibronectin; and colonic myofibroblasts, which primarily produce collagen (types I, III, and V), chondroitin sulfate proteoglycans, hyaluronic acid, fibronectin, and tenascin-C. These are “naturally occurring ECMs.” Naturally occurring ECMs may be commercially available. Examples of commercially available extracellular matrices include extracellular matrix proteins (Invitrogen) and basement membrane preparations from Angelbreth-Holm-Swarm (EHS) mouse sarcoma cells (e.g., Cultrex® basement membrane extract (Trevigen, Inc.), type I collagen (Invitrogen), Vitrogel® (TheWell Bioscience Inc.), or Matrigel® (BD Biosciences)). That is, the composition according to the present invention can be embedded in the above-mentioned supports and utilized for transplantation, or mixed and utilized for transplantation, as needed.
[0070] In addition, dimethyl sulfoxide (DMSO) and the like can be added for the purpose of protecting cells, antibiotics and the like can be added for the purpose of preventing bacterial contamination, and various components (vitamins, cytokines, growth factors, steroids, etc.) can be added to the transplant material of the present invention for the purpose of inducing cell activation, proliferation, or differentiation.
[0071] The pharmaceutical composition of the present invention may include conventional pharmaceutically acceptable inert carriers and diluents. Pharmaceutically acceptable carriers and diluents that may be included in the pharmaceutical composition of the present invention include, but are not limited to, excipients such as starches, sugars, and mannitol; fillers and extenders such as calcium phosphate; cellulose derivatives such as carboxymethylcellulose and hydroxypropylcellulose; binders such as gelatin, alginates, and polyvinyl pyrrolidone; lubricants such as talc, calcium stearate, hydrogenated castor oil, and polyethylene glycol; disintegrants such as povidone and crospovidone; and surfactants such as polysorbates, cetyl alcohol, and glycerol. The pharmaceutically acceptable carriers and diluents may be biologically and physiologically compatible with a subject. Diluents include, but are not limited to, saline, aqueous buffers, solvents, and / or dispersion media. Additionally, for example, injectable formulations may further include preservatives, analgesics, solubilizers, or stabilizers, while topical formulations may further include bases, excipients, lubricants, or preservatives.
[0072] The pharmaceutical composition of the present invention may be used unfrozen or frozen for later use. If frozen, standard cryopreservatives (e.g., DMSO, glycerol, Epilife® cell freezing medium (Cascade Biologics)) may be added to the cell population prior to freezing.
[0073] The composition of the present invention contains 1.0×10 per 1 ml 3 Dog or 1.0×10 5 Dog, preferably 1.0×10 5 It may contain dog cells.
[0074] The pharmaceutical composition of the present invention can be formulated into a unit dosage form pharmaceutical preparation suitable for administration into the body of a patient according to a conventional method in the pharmaceutical field and administered, and the preparation contains an effective dosage amount through one or more administrations. Preferred dosage forms for this purpose are parenteral administration preparations such as injections, infusions, and transplants. In addition, the pharmaceutical composition may contain a conventional inert pharmaceutically acceptable carrier and diluent. The pharmaceutically acceptable carrier and diluent may be biologically and physiologically compatible with mesenchymal stromal cells and the recipient to be transplanted thereto. Diluents include, but are not limited to, saline, aqueous buffers, solvents, and / or dispersion media. In addition, for example, in the case of injections, the composition may further contain a preservative, analgesic, solubilizer, or stabilizer, and in the case of topical administration, the composition may further contain a base, excipient, lubricant, or preservative.
[0075] The compositions of the present invention may be used unfrozen or frozen for later use. If frozen, standard cryopreservatives (e.g., DMSO, glycerol, Epilife® cell freezing medium (Cascade Biologics)) may be added to the cell population prior to freezing.
[0076] In addition, it can be transplanted and administered using a commonly used administration method in the art, and preferably, direct engraftment or transplantation is possible at the disease site of the patient requiring treatment, but is not limited thereto. In addition, the administration can be both non-surgical administration using a catheter and surgical administration methods such as injection or transplantation after incision of the disease site. The dosage is 5 x 10 5 ~10 8 / 60kg adult or, 5 x 10 5 ~10 8 / Can be administered once. However, it should be understood that the actual dosage of the active ingredient should be determined in light of various related factors such as the disease to be treated, the severity of the disease, the route of administration, the patient's weight, age, and sex, and therefore, the dosage does not limit the scope of the present invention in any way.
[0077] The present invention also provides a pharmaceutical composition comprising epithelial progenitor cells or stem cells within a minor salivary gland duct for use in preventing or treating salivary gland diseases.
[0078] The present invention also provides the use of epithelial progenitor cells or stem cells within the ducts of minor salivary glands in the manufacture of a medicament for use in the prevention or treatment of salivary gland diseases.
[0079] A method for treating a salivary gland disease is provided, comprising administering to a subject in need thereof epithelial progenitor cells or stem cells within a mature salivary gland duct.
[0080] Subject means any animal, including humans, monkeys, cows, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, rats, rabbits or guinea pigs, in which a salivary gland disease has developed or may develop.
[0081] Unless otherwise defined, all technical terms used in this invention have the same meaning as commonly understood by those skilled in the art. While preferred methods and samples are described herein, similar or equivalent methods are also included within the scope of the present invention. The contents of all publications cited as references herein are incorporated herein by reference.
[0082] The present invention provides epithelial progenitor cells or stem cells within the ducts of the minor salivary glands for therapeutic purposes, thereby safely alleviating inflammation within the salivary glands and improving saliva production, effectively treating salivary gland diseases. Furthermore, unlike existing mesenchymal stem cell treatments, this cell line not only exhibits superior efficacy in that it can immediately and directly regenerate damaged areas, but also maintains its properties despite the application of simplified passage methods and freeze-thaw techniques.
[0083] Figure 1 is a diagram illustrating the overall flow of obtaining, mass culturing, and confirming therapeutic efficacy of epithelial progenitor cells or stem cells in the salivary gland duct of the present invention.
[0084] Figure 2 is a diagram showing the results of confirming epithelial progenitor cells or stem cells in the salivary gland duct cultured according to an embodiment of the present invention.
[0085] FIG. 3 is a diagram confirming that epithelial progenitor cells or stem cells in the salivary gland ducts cultured according to an embodiment of the present invention are capable of self-proliferation even after long-term culture.
[0086] Figure 4 is a diagram showing the representative expression difference results from mesenchymal stem cells through flow cytometry analysis of epithelial progenitor cells or stem cells in the salivary gland ducts cultured according to an embodiment of the present invention.
[0087] FIG. 5 is a diagram showing the results of performing quantitative nucleic acid amplification on epithelial progenitor cells or stem cells in salivary gland ducts cultured according to an embodiment of the present invention to confirm the level of gene expression.
[0088] Figure 6 is a diagram showing the results of confirming the organoid-generating ability of epithelial progenitor cells or stem cells in the salivary gland duct cultured according to an embodiment of the present invention.
[0089] Figure 7 is a diagram showing the results of an experiment in which protein expression of epithelial progenitor cells or stem cells in salivary gland ducts cultured according to an embodiment of the present invention was confirmed through immunofluorescence staining.
[0090] FIG. 8 is a diagram showing the results of an experiment on the salivary secretion function of the salivary glands of Sjogren's syndrome-induced mice in which cultured salivary gland epithelial progenitor cells or stem cells were directly administered into the ducts according to an embodiment of the present invention.
[0091] FIG. 9 is a diagram showing the results of an autoantibody ELISA experiment on a Sjogren's syndrome-induced mouse in which cultured salivary gland duct epithelial progenitor cells or stem cells were injected into the duct according to an embodiment of the present invention, and the results of an experiment to restore the expression of AQP5 genes and KRT5 genes in the salivary gland.
[0092] FIG. 10 is a diagram showing the results of an experiment on body weight and salivary secretion function of salivary glands in a group of non-irradiated and irradiated mice with reduced salivary gland function, in which cultured salivary gland ductal epithelial progenitor cells or stem cells were directly administered into the ducts according to an embodiment of the present invention.
[0093] FIG. 11 is a diagram showing the results of a histological staining experiment on a salivary gland dysfunction mouse into which cultured salivary gland duct epithelial progenitor cells or stem cells were injected into the duct according to an embodiment of the present invention, and the results of an experiment to restore the expression of the AQP5 gene in the salivary gland.
[0094] To aid in understanding the present invention, examples are presented. The following examples are provided solely to facilitate a better understanding of the present invention, and the scope of the present invention is not limited by the examples.
[0095] The experimental progress according to the present invention was carried out in the order shown in Fig. 1. Specifically, epithelial progenitor cells or stem cells in the ducts of the minor salivary glands were obtained, and conditions for mass culture were completed under xeno-free, serum-free, and feeder cell-free conditions, and it was confirmed that salivary gland function was normalized using the isolated monoclonal epithelial progenitor cells or stem cells in the ducts of the minor salivary glands.
[0096] Example 1. Production of monoclonal minor salivary gland ductal epithelial progenitor cells or stem cells.
[0097] 1. Reagent
[0098] The following reagents were used in the present invention.
[0099] DermaCult™Keratinocyte Expansion Medium (# 100-0500, STEMCELL), DermaCult™Keratinocyte Expansion Supplement (# 100-0502, STEMCELL), CnT-Prime Epithelial Proliferation Medium (# CnT-PR, CellnTec), Primocin (# anti-pm, Invivogen), Y-27632 dihydrochloride (# TB1254-GMP, Tocris), A83-01 (# TB2939-RMU, Tocris), DMH-1 (# 4126, Tocris), LDN 193189 dihydrochloride (# TB6053-GMP, Tocris),CTS™DPBS, calcium, magnesium (# A1285801, Gibco), CTS™DPBS (1×), without calcium chloride, without magnesium chloride (# A1285601, Gibco), Collagenase NB6 GMP grade (N0002779, Nordmark), CTS™TrypLE™ Select Enzyme (# A1285901, Gibco), 100x20mm culture dish (# 150466, Thermo), 48 well culture plate (#30048, SPL), 24 well culture plate (#30024, SPL), 12 well culture plate (# 30012, SPL), 6 well culture plate (# 30006, SPL), 25cm 2 cell culture plate (# 70025, SPL), 75cm 2 cell culture plate (# 70075, SPL), 175cm 2cell culture plate (# 70175, SPL), STEM-CELLBANKER-GMP Grade (# 11924, AMSBIO), Strainer (# 93070, SPL), Falcon®5 mL Round Bottom Polystyrene Test Tube, with Cell Strainer Snap Cap (# 352235, Falcon), 1.5 mL Eppendorf tube, 5 mL conical Tube (# 51105, SPL), 15 mL conical Tube (# 51115, SPL), 50 mL conical Tube (# 51150, SPL).
[0100] 2. Obtaining human salivary gland epithelial cells from tissue
[0101] During surgical procedures such as tumor removal, normal tissues of the minor salivary glands not invaded by the tumor were collected for biopsy or percutaneous needle biopsy, or 1-2 lobes were collected from the minor salivary glands of patients suspected of having Sjögren's disease. These were placed in CTS™DPBS, calcium, magnesium and stored in a 4℃ refrigerator until the experiment on the same day or the next day. Collagenase was added to CTS™DPBS, calcium, magnesium to make 0.4 U / mL, and Y27632 was added to the enzyme solution to a concentration of 10 μM. 1 mL was prepared per 10 mg of tissue, and if the tissue weight was less than 10 mg, the minimum volume was 1 mL. The tissue was placed in a petri dish, finely ground using a scalpel blade, and added to the prepared enzyme solution for reaction at 37℃ for 1 hour. The solution was inverted once every 10 minutes to ensure good mixing of the solution and the tissue. Centrifuge at 300g, 5 min, 4℃, remove the enzyme solution, add CTS™DPBS (1×), without calcium chloride, without magnesium chloride, twice the volume of the enzyme solution, centrifuge again at 300g, 5 min, 4℃, and remove the DPBS. Add CTS™TrypLE™ Select Enzyme at 1 mL per 50 mg of the original tissue weight. Add Y27632 to a concentration of 10 μM (add 1 mL for tissue weight less than 50 mg), and incubate at 37℃ for 20 minutes, inverting every 10 minutes to mix evenly. After mixing with an equal volume of culture medium, pass through a 70 μm strainer, and then through a Falcon tube with strainer, centrifuge at 300g, 5 min, 4℃, and remove the supernatant. Afterwards, the culture medium was added again, centrifuged at 300g, 5 min, 4℃, the supernatant was removed, and the cells were counted.
[0102] 3. Isolation of human salivary gland epithelial monoclonal cells
[0103] The cells were homogenized in 10 mL of culture medium, evenly distributed on a 100x20 mm culture dish, and stored in an incubator at 37°C and 5% CO2. The composition of the culture medium was set as shown in [Table 1].
[0104] Culture medium 1 Final concentration Culture medium 2 Final concentration Dermacult Basal Medium CnT-PR Basal Medium Dermacult Supplement 1X--Prinmocin 100 μg / ml LPrinmocin 100 μg / ml LY-2763210 μMY-2763210 μMA83-011 μMA83-011 μMLDN1931890.1 μMLDN1931890.1 μM
[0105] To perform the layer culture (SCM) method to isolate epithelial monoclonal cells, after 2 hours, the culture medium containing the cells was transferred to a new 100x20 mm culture dish, and this was repeated twice more. Then, after 24 hours, the dish was re-cultured, and the old culture medium was removed and replaced with new culture medium at intervals of 2-3 days. After confirming that colonies were formed, the size of the cell cluster forming one colony was 1 cm 2 After the passage, the culture medium was removed, marked with a hydrophobic pen, and the remaining culture medium was removed using 1x PBS. After adding 50-100 μL of TrypLE and Y27632, it was stored in an incubator at 37°C, 5% CO2 for 15 minutes. The cell clusters detached from the dish by TrypLE were placed into separate 1.5 ml tubes, and 1 ml of culture medium was added. After centrifugation at 300g and 4°C for 5 minutes, the supernatant was removed, and 250 μL of new culture medium was homogenized and spread into each well of a 48-well plate for each cell cluster.
[0106] 4. Proliferation of salivary gland epithelial cells separated into single cell groups
[0107] After removing the culture medium at 2-3 day intervals, subsequent cultures were performed by replacing it with new culture medium. Passaging was performed when each well of a 48-well plate was 80-90% full of cells. At this time, the composition of the culture medium used for passage was used in [Table 2]. After removing the culture medium, the remaining culture medium was removed using PBS. After that, TrypLE express (approximately 125 μl) was added in an amount that covered the bottom of the well, and the cells were stored in an incubator at 37°C and 5% CO2 for 15 minutes. The cells detached from the culture plate by TrypLE express were placed in separate 5 ml tubes, and the culture medium in [Table 2] was added to make a total volume of 1 ml to neutralize. After centrifugation at 300 g for 5 minutes at 4°C, the supernatant was removed, and 0.5 ml of the culture medium in [Table 2] was homogenized and spread on each well of a 24-well plate according to cell cluster. Then, the existing culture medium was removed at intervals of 2-3 days and replaced with new culture medium. The above subculture was scaled up as follows: 24-well culture plate (0.5 mL), 12-well culture plate (1 mL), 6-well culture plate (2 mL). 25 cm 2 cell culture flask (5 mL), 75 cm 2 cell culture flask (15 mL), 175 cm 2 Cell culture flask (35 mL) was used (the amount of culture medium added is indicated in parentheses).
[0108] Cells from 6 wells can be used for various experiments, and when passaged, the ratio was 1:2 to 1:10. When population doubling was confirmed and the proliferation rate was not exponential, the cells were judged to be aged and discarded.
[0109] Culture medium 1 Final concentration Culture medium 2 Final concentration Dermacult Basal Medium CnT-PR Basal Medium Dermacult Supplement 1 X--Y-2763210 μM Y-2763210 μMA83-011 μMA83-011 μMLDN1931890.1 μMLDN1931890.1 μM
[0110]
[0111] Example 2. Characterization of monoclonal minor salivary gland duct epithelial progenitor cells or stem cells.
[0112] The following experiments were initiated when the clones successfully proliferated in Example 1 above reached 70-80% confluency under culture conditions.
[0113] Specifically, the morphological characteristics of the cells were confirmed using an optical microscope. In addition, the population doubling of cells was confirmed using the trypan blue exclusion method.
[0114] Additionally, flow cytometry was used to confirm the expression of stem cell-related proteins on the cell surface.
[0115] Additionally, the gene expression level of the cells according to the present invention was confirmed using quantitative nucleic acid amplification.
[0116] Finally, differentiation potential was tested through three-dimensional culture using Matrigel.
[0117] 1. Analysis of cell morphological characteristics
[0118] Before passage, morphological changes were confirmed using an optical microscope, and this is shown in Fig. 2. As can be seen from Fig. 2, the cells according to the present invention were confirmed to maintain a polygonal shape, which is a characteristic of epithelial progenitor cells or stem cells in the minor salivary gland ducts. When population doubling of the cells according to the present invention was confirmed using the trypan blue stain exclusion method, it was confirmed that self-renewal was possible even after long-term culture, as shown in Fig. 3.
[0119] 2. Flow cytometry results
[0120] Flow cytometry was performed using cells that had proliferated to about 70-80%. The culture medium was removed and washed with DPBS. TrypLE express was added and the cells were kept in an incubator at 37°C and 5% CO2 for 15 minutes and confirmed to have detached as single cells. The cells detached by TrypLE express were neutralized by adding culture medium, centrifuged at 300g and 4°C for 5 minutes, the supernatant was removed, and the pellet was dissolved in DPBS. After filtering the cells into a FACS tube, the number of cells was measured and 1X10 per tube. 6The cells were calculated to enter. After centrifugation at 500g and 4℃ for 5 minutes, Zombie Violet Fixable Viability Dye was mixed with DPBS, placed in a tube, blocked from light, and incubated at room temperature for 15 minutes. FACS buffer containing 0.5% BSA and 0.05% sodium azide in DPBS was added, and centrifuged at 500g and 4℃ for 5 minutes. Then, the supernatant was removed, TruStain FcX was mixed with FACS buffer, placed in a tube, blocked from light, and incubated at room temperature for 10 minutes. Fluorescent-conjugated antibodies were mixed with FACS buffer, placed in a tube, blocked from light, and incubated at 4℃ for 30 minutes. FACS buffer was added to perform vortexing, and centrifugation was performed twice at 500g and 4℃ for 5 minutes, followed by analysis using a flow cytometry device.
[0121] The results are shown in Fig. 4. As can be confirmed through Fig. 4, the cells according to the present invention exhibited the characteristics of high expression of CD29, CD44, CD49f, CD146, and CD166. These characteristics showed that the cells according to the present invention had the characteristics of salivary gland basal cells while still having high differentiation potential. On the other hand, luminal cell markers such as CD24, CD26, and CD117 were not expressed, and CD34 and CD90 were hardly expressed or had very low expression levels. In particular, the negative expression of CD34 and CD90 was different from the characteristics exhibited by mesenchymal stem cells (MSCs), confirming that the cells of the present invention exhibited a clear characteristic difference from MSCs.
[0122] 3. Confirmation of gene expression using quantitative nucleic acid amplification
[0123] (1) Reagent
[0124] TRIzol™ Reagent (Invitrogen™ #15596026), PrimeScript™ RT reagent Kit (Takara #RR037A), SensiFAST™ SYBR® Lo-ROX Kit (Bioline #BIO-94020)
[0125] (2) Experimental method
[0126] After removing the culture medium, the cells were washed by adding 1 mL of DPBS to the culture dish containing the cells, and 1 mL of TRIZOL was added to lyse the cells. RNA was isolated according to the protocol provided by the manufacturer and dissolved in RNase-free DW. The amount of RNA was quantified using Nanodrop and calculated to contain 500 ng of RNA per tube, and cDNA was synthesized using the PrimeScript™ RT reagent Kit. Afterwards, real-time PCR assay was performed using the SensiFAST™ SYBR® Lo-ROX Kit. The synthesis and analysis were performed according to the protocol provided by the manufacturer.
[0127] The results are shown in Fig. 5. As can be confirmed through Fig. 5, the cells according to the present invention showed that the RNA of KRT5 and KRT19, which are salivary gland progenitor cell markers, increased after subculture. This characteristic showed that the cells according to the present invention have the characteristics of salivary gland epithelial progenitor cells or stem cells. In addition, the expression level of CDKN2A RNA, which is a senescence-related marker, showed a characteristic of decreasing after subculture. This showed that the cells according to the present invention can be cultured for a long period of time without senescence. In addition, the RNA of Vimentin and Fibronectin-1, which are mesenchymal cell markers, showed a characteristic of decreasing the expression level after subculture. Through this, it was shown that the cells according to the present invention have the characteristics of epithelial progenitor cells or stem cells.
[0128] 4. Identification of differentiation through 3D culture
[0129] (1) 3-dimensional culture test for differentiation
[0130] Advanced DMEM / F12 (ADF12) (#12634010, Gibco), HEPES (#15630-080, Gibco), GlutaMAX (#35050-061, Gibco), Y-27632 dihydrochloride (#1254, Tocris), 1×HBSS solution (#14025092, Gibco), Collagenase, type II (#4176, Worthington), Matrigel (#356231, Corning), TrypLE express (#12605-010, Life technologies), CellBanker 1 (Zenoaq), BSA (Bovine Serum Albumin; #BSA-68700-1kg, LSP), Primocin (#ant-pm, Invivogen), B-27 Supplement (50X), serum free (#17504-044, Gibco), NAC (N-acetyl-cysteine; #A9165, Sigma), Nicotinamide (#N0636, Sigma), A83-01 (#2939, Tocris), Prostaglandin E2 (#2296, Tocris), Recombinant RSPO3-Fc fusion protein conditioned medium (hRSPO3-CM) (R001, U-Protein Express BV), Noggin-Fc Fusion Protein conditioned medium (hNOG-CM) (#N002, U-Protein Express BV), Nrg1 (Neuregulin-1; #100-03, Peprotech), FGF2 (#100-18B, Peprotech), FGF10 (#100-26, Peprotech).
[0131] (2) Production and culture maintenance of organoids derived from minor salivary glands of Sjogren's syndrome patients
[0132] After thawing the salivary gland cells obtained from the tissue stored in a nitrogen tank until slushy, 1000 μL of Advanced DMEM / F12 was added and centrifuged at 500 g for 5 minutes. The supernatant was removed and 3.0 X 10 cells were added per well of a 24-well plate. 3 It was calculated to be a cell number. 40 μL of Matrigel per well was mixed with the centrifuged cell pellet in a 24-well plate placed in a 37℃ incubator for more than 30 minutes, and then placed in the well in the form of a dome. The culture medium conditions of the organoids derived from the salivary glands of patients with Sjögren's syndrome are as shown in [Table 3]. To maintain the culture, the culture medium was replaced with fresh medium every 2-3 days. Before passage, the shape and size of the organoids were checked using an optical microscope as shown in Figure 6 to confirm that the formation of the organoids was maintained. Through the formation of the organoids and maintenance of the culture, the differentiation potential of epithelial cells derived from the minor salivary gland was confirmed.
[0133] Advanced DMEM / F12Glutamax2 mMHEPES10 mMPrimocin100 μg / mLB27 vit A+1
[0134] * Y-27632 was removed after 7 days of treatment from the start of organoid culture.
[0135]
[0136] Example 3. Confirmation of protein expression in ductal progenitor cells of the small glands using immunofluorescence staining.
[0137] The expression of epithelial progenitor or stem cell markers in the salivary gland ducts was confirmed by immunofluorescence staining using cells that had proliferated to 70-80%. The cell culture medium was removed, washed with DPBS, and fixed for 10 minutes with 4% PFA or a 1:1 ratio of ethanol and methanol. After fixation, normal donkey serum was added and incubated for 1 hour to prevent nonspecific binding. After washing with DPBS, the primary antibody was attached and incubated overnight at 4°C. The secondary antibody was attached for 1 hour at room temperature, followed by mounting solution, coverslip, and drying. Fluorescence microscopy revealed no expression of salivary gland acinar cell markers MIST1 and AQP5. KRT5, a marker of salivary gland basal duct cells, was expressed, but KRT7, a marker of ductal cells, was not. In addition, it was confirmed that E-Cadherin, an epithelial cell marker, was expressed, but Vimentin, a mesenchymal stem cell marker, was not expressed, as shown in Figure 7.
[0138]
[0139] Example 4. Confirmation of therapeutic efficacy in a mouse model of salivary gland disease.
[0140] The therapeutic efficacy was confirmed by treating human minor salivary gland epithelial progenitor cells or stem cells according to the present invention into the salivary gland ducts of Sjogren's syndrome-induced mice.
[0141] Specifically, Sjogren's syndrome-induced mice (ESS) were produced by mixing a mouse salivary gland-derived antigen with an adjuvant and injecting it into a homologous mouse to induce an antigen-antibody response. Then, cells according to the present invention were injected into the salivary gland ducts of the mice using a catheter and tube, and the therapeutic efficacy thereof was confirmed.
[0142] The therapeutic efficacy was confirmed by measuring the Saliva Flow rate and ELISA analysis in mouse blood.
[0143] To measure the saliva flow rate, the weight of cotton to be bitten in the mouse mouth of the experimental mouse model was measured. Then, the mice were anesthetized by intraperitoneal injection of anesthetics such as Ketamine (100 mg / kg) and Xylazine (15 mg / kg). Next, pilocarpine (0.5 mg / kg) was injected intraperitoneally, and immediately after injection, cotton was bitten in the mouse mouth, and after 5 minutes, the weight was measured. The cotton biting process was repeated for a total of 25 minutes, and the weight was measured and added up to calculate the amount of saliva secreted.
[0144] The results are shown in Fig. 8. As can be confirmed through Fig. 8, the result of confirming the decrease in saliva secretion, a representative symptom of Sjögren's syndrome, confirmed that the saliva secretion ability was restored to the normal mouse level in a dose-dependent manner in the treatment group injected with the cells according to the present invention compared to when only the excipient, physiological saline, was injected. Through this, it was confirmed that the cells according to the present invention exhibit excellent efficacy in restoring salivary gland function.
[0145] Next, changes in secreted factors were confirmed through ELISA analysis in mouse blood.
[0146] Experiments were performed using the Mouse ANA ELISA Kit, 96T (#EM1607, Finetest) according to the manufacturer's protocol. Mice were euthanized with CO2 gas 14 days after cell administration, the end point of the experiment. After an abdominal incision, blood was collected from the abdominal aorta using a 1-ml syringe. The supernatant was centrifuged at 1,000 × g for 15 minutes, and the separated sample was subjected to ELISA analysis according to the kit protocol.
[0147] The results are shown in Fig. 9. As can be confirmed through Fig. 9, the results of confirming autoantibodies through ELISA in mouse blood confirmed the effect of treating Sjögren's syndrome, an autoimmune disease, through the decrease in autoantibody concentration in a dose-dependent manner in the cell-injected group. Furthermore, the expression of the acinar marker AQP5 and the basal marker KRT5 in the salivary gland tissue increased in a dose-dependent manner compared to the control group, confirming the effect of restoring salivary gland function.
[0148]
[0149] Example 5. Confirmation of therapeutic efficacy in a mouse model of reduced salivary gland function.
[0150] A mouse model of salivary gland dysfunction caused by radiation was prepared, and the therapeutic efficacy was confirmed by treating cells according to the present invention into the salivary gland ducts of the model.
[0151] Specifically, mice with reduced salivary gland function were produced by irradiating a single 15 Gy X-ray to the local area where the salivary glands of the mouse are located using a Biological X-Ray Irradiator (X-RAD) device (Precision X-Ray Inc. (USA)). Thereafter, cells according to the present invention were injected into the salivary gland ducts of the mice using a catheter and tube, and the therapeutic efficacy thereof was confirmed.
[0152] The therapeutic efficacy was confirmed through Saliva Flow rate measurement, histological staining, and quantitative nucleic acid amplification.
[0153] To measure the saliva flow rate, the weight of cotton that was placed in the mouth of the mouse was measured in the mouse model tested above. Then, the mice were anesthetized by intraperitoneal injection of anesthetics such as Ketamine (100 mg / kg) and Xylazine (15 mg / kg). Next, pilocarpine (0.5 mg / kg) was injected intraperitoneally, and the cotton was placed in the mouth of the mouse immediately after injection. After 15 minutes, it was removed and weighed, and the amount of saliva secreted was calculated.
[0154] The results are shown in Fig. 10. Specifically, as a result of confirming the decrease in saliva secretion, which is one of the symptoms of decreased salivary gland function, it was confirmed that the saliva secretion function was restored to the normal mouse level in a dose-dependent manner in the treatment group injected with the cells according to the present invention compared to when only saline, which is an excipient, was injected. Through this, it was confirmed that the cells according to the present invention exhibit excellent efficacy in restoring salivary gland function.
[0155] Next, histological changes in the salivary glands of mice were confirmed through hematoxylin and eosin staining.
[0156] Experiments were performed using the H&E Staining Kit (#ab245880, Abcam) according to the manufacturer's protocol. Twenty-one days after cell administration, the experimental end point, mice were euthanized with CO2 gas. Salivary glands were isolated by incision, fixed in 4% PFA for 24 hours, and paraffin blocks were prepared. Paraffin sections were then sectioned to a thickness of 5 μm. Histological staining of the salivary gland paraffin sections was performed according to the kit protocol.
[0157] The results are shown in Fig. 11. The degree of salivary gland duct damage was confirmed through staining in mouse salivary glands. The cell-injected group showed a decrease in ductal damage, confirming its effectiveness in treating salivary gland dysfunction. Furthermore, the expression of AQP5, a marker of acinar cells, increased in salivary gland tissue compared to the control group, confirming its effect in restoring salivary gland function.
Claims
1. A pharmaceutical composition for preventing or treating salivary gland diseases, comprising epithelial progenitor cells or stem cells in the salivary gland ducts.
2. A pharmaceutical composition for preventing or treating salivary gland disease, wherein the epithelial progenitor cells or stem cells in the salivary gland duct of the first paragraph are cells derived from salivary gland tissue.
3. A pharmaceutical composition for preventing or treating a salivary gland disease, wherein the epithelial progenitor cells or stem cells in the salivary gland duct of the first paragraph are cultured in the presence of a ROCK inhibitor, a TGF-beta inhibitor, and a BMP inhibitor.
4. A pharmaceutical composition for preventing or treating salivary gland disease, wherein the ROCK inhibitor is Y-27632, Fasudil or H-1152 in the third paragraph.
5. A pharmaceutical composition for preventing or treating salivary gland disease, wherein the TGF-beta inhibitor in the third paragraph is any one selected from the group consisting of A83-01, SB-431542, SB-505124, SB-525334, SD-208, RepSOX, LY-36494, and SJN-2511.
6. A pharmaceutical composition for preventing or treating salivary gland disease, wherein the BMP inhibitor in paragraph 3 is any one selected from the group consisting of Noggin, Dorsomorphin, Gremlin 1, DMH1, and LDN-193189.
7. A pharmaceutical composition for preventing or treating salivary gland disease, wherein the ROCK inhibitor is Y-27632, the TGF-beta inhibitor is A83-01, and the BMP inhibitor is DMH1 or LDN193189 in the third paragraph.
8. A pharmaceutical composition for preventing or treating a salivary gland disease, wherein the ROCK inhibitor is Y-27632, the TGF-beta inhibitor is A83-01, and the BMP inhibitor is LDN193189 in paragraph 7.
9. A pharmaceutical composition for preventing or treating salivary gland disease, wherein the culture is performed under an epithelial cell culture medium in the third paragraph.
10. A pharmaceutical composition for preventing or treating a salivary gland disease, wherein the epithelial progenitor cells or stem cells in the salivary gland ducts of the first paragraph highly express at least one cell surface marker selected from the group consisting of CD29, CD44, CD49f, CD146, CD166, KRT5, KRT19, and E-Cadherin, and do not express at least one cell surface marker selected from the group consisting of CD24, CD26, CD34, CD90, CD117, MIST, AQP5, KRT7, CDKN2A, Fibronectin-1, and Vimentin.
11. A pharmaceutical composition for preventing or treating a salivary gland disease, wherein the culture is cultured under xeno-free, serum-free, feeder-free or all of these conditions in the third paragraph.
12. In the first paragraph, the epithelial progenitor cells or stem cells in the salivary gland ducts are (1) A step of culturing cells derived from a minor salivary gland under a medium composition containing a ROCK inhibitor, a TGF-beta inhibitor, and a BMP inhibitor; and (2) a step of culturing and proliferating epithelial progenitor cells or stem cells within the minor salivary gland ducts separated by culture in step (1) under a medium containing a ROCK inhibitor, a TGF-beta inhibitor, and a BMP inhibitor; A pharmaceutical composition for preventing or treating a salivary gland disease, obtained through the steps of:
13. A pharmaceutical composition for preventing or treating salivary gland disease, wherein the ROCK inhibitor is Y-27632, the TGF-beta inhibitor is A83-01, and the BMP inhibitor is DMH1 or LDN193189 in claim 12.
14. A pharmaceutical composition for preventing or treating a salivary gland disease, wherein the salivary gland disease in paragraph 1 is any one selected from the group consisting of xerostomia, infectious acute sialadenitis, infectious chronic sialadenitis, salivary gland tuberculosis, Sjogren's syndrome, sialolithiasis, salivary duct stenosis, sialadenosis, salivary gland tumor, salivary gland dysfunction due to aging, salivary gland dysfunction due to drugs, and salivary gland dysfunction due to radiation therapy.
15. A pharmaceutical composition for preventing or treating a salivary gland disease, wherein the salivary gland disease in claim 14 is Sjogren's syndrome.
16. A pharmaceutical composition for preventing or treating a salivary gland disease, wherein the composition is administered through a salivary gland duct in the first paragraph.
17. A method for preventing or treating a salivary gland disease, comprising administering to a subject in need thereof a therapeutically effective amount of intraductal epithelial progenitor cells or stem cells of a minor salivary gland.
18. A method for preventing or treating a salivary gland disease according to claim 17, wherein the salivary gland disease is any one selected from the group consisting of xerostomia, infectious acute sialadenitis, infectious chronic sialadenitis, salivary gland tuberculosis, Sjogren's syndrome, sialolithiasis, salivary duct stenosis, sialadenosis, salivary gland tumor, salivary gland dysfunction due to aging, salivary gland dysfunction due to drugs, and salivary gland dysfunction due to radiation therapy.
19. A method for preventing or treating a salivary gland disease in claim 18, wherein the salivary gland disease is Sjogren's syndrome.
20. Use of epithelial progenitor cells or stem cells in the ducts of minor salivary glands for the manufacture of a medicament for the prevention or treatment of salivary gland diseases.
21. In the 20th paragraph, the salivary gland disease is any one selected from the group consisting of xerostomia, infectious acute sialadenitis, infectious chronic sialadenitis, salivary gland tuberculosis, Sjogren's syndrome, sialolithiasis, salivary duct stenosis, sialadenosis, sialadenosis, salivary gland tumor, salivary gland dysfunction due to aging, salivary gland dysfunction due to drugs, and salivary gland dysfunction due to radiation therapy.
22. The use according to claim 21, wherein the salivary gland disease is Sjogren's syndrome.
23. A pharmaceutical composition comprising epithelial progenitor cells or stem cells within a minor salivary gland duct for use in the prevention or treatment of salivary gland diseases.
24. A pharmaceutical composition according to claim 23, wherein the salivary gland disease is any one selected from the group consisting of xerostomia, infectious acute sialadenitis, infectious chronic sialadenitis, salivary gland tuberculosis, Sjogren's syndrome, sialolithiasis, salivary duct stenosis, sialadenosis, salivary gland tumor, aging-induced salivary gland dysfunction, drug-induced salivary gland dysfunction, and radiation-induced salivary gland dysfunction.
25. A pharmaceutical composition according to claim 24, wherein the salivary gland disease is Sjogren's syndrome.
Citation Information
Patent Citations
KR20210121365A
